Trilaciclib, Cemiplimab & GU Updates
from OncoPharm Hosted by John Bossaer
Topics covered: 1. Trilaciclib's approval to minimize bone marrow suppression 2. Cemiplimab's approval for mNSLC with high PD-L1 expression 3. A brief anti-BCMA CAR-T phase II trial in multiple myeloma 4. Confirmation of enfortumab vedotin's benefit in metastatic bladder cancer 5. More of the same with lenvatinib + pembrolizumab in mRCC
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 19 minutes long.
When was this OncoPharm episode published?
This episode was published on February 25, 2021.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.